On July 16, 2026 Eli Lilly announced the acquisition of AtaiBeckley for up to $3.8B, gaining BPL-003, a synthetic 5-MeO-DMT nasal spray in Phase 3 for.
Contact Us | Apply Now | Call +1-323-612-2024